2016
Moderate Alcohol Consumption and Chronic Disease: The Case for a Long‐Term Trial
Mukamal KJ, Clowry CM, Murray MM, Hendriks HF, Rimm EB, Sink KM, Adebamowo CA, Dragsted LO, Lapinski PS, Lazo M, Krystal JH. Moderate Alcohol Consumption and Chronic Disease: The Case for a Long‐Term Trial. Alcohol Clinical And Experimental Research 2016, 40: 2283-2291. PMID: 27688006, PMCID: PMC5073014, DOI: 10.1111/acer.13231.Peer-Reviewed Original ResearchConceptsModerate alcohol consumptionChronic diseasesAlcohol consumptionRandomized trialsLong-term clinical trialsCoronary heart diseaseMajor chronic diseasesStrong epidemiological associationLong-term trialsGold standard evidenceNutritional interventionHeart diseaseClinical trialsBreast cancerEpidemiological associationModerate drinkingYears durationClinical investigatorsBiological mediatorsAvailable evidenceDiseaseObserved associationsTrialsStandard evidenceVariety of settings
2014
N-Methyl-D-Aspartate Receptor Antagonist Effects on Prefrontal Cortical Connectivity Better Model Early Than Chronic Schizophrenia
Anticevic A, Corlett PR, Cole MW, Savic A, Gancsos M, Tang Y, Repovs G, Murray JD, Driesen NR, Morgan PT, Xu K, Wang F, Krystal JH. N-Methyl-D-Aspartate Receptor Antagonist Effects on Prefrontal Cortical Connectivity Better Model Early Than Chronic Schizophrenia. Biological Psychiatry 2014, 77: 569-580. PMID: 25281999, DOI: 10.1016/j.biopsych.2014.07.022.Peer-Reviewed Original ResearchConceptsHealthy volunteersFunctional connectivityKetamine effectsChronic schizophreniaIllness progressionChronic illnessHigh riskRecent pharmacologic studiesReceptor antagonist effectsAspartate glutamate receptorsStages of schizophreniaCourse of schizophreniaGlutamate dysfunctionPharmacologic modelsPrefrontal cortex functionIllness stageNMDAR antagonistsFunctional dysconnectivityGlutamate receptorsPharmacologic studiesHealthy subjectsSchizophrenia onsetFunctional alterationsDevelopment of therapeuticsAntagonist effectsSymptom structure and severity: A comparison of responses to the positive and negative syndrome scale (PANSS) between patients with PTSD or schizophrenia
Stefanovics EA, Krystal JH, Rosenheck RA. Symptom structure and severity: A comparison of responses to the positive and negative syndrome scale (PANSS) between patients with PTSD or schizophrenia. Comprehensive Psychiatry 2014, 55: 887-895. PMID: 24602497, DOI: 10.1016/j.comppsych.2014.01.014.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntipsychotic AgentsChronic DiseaseCombat DisordersDiagnosis, DifferentialDouble-Blind MethodFemaleHumansMaleMiddle AgedPsychiatric Status Rating ScalesPsychometricsRisperidoneSchizophreniaSchizophrenic PsychologyStress Disorders, Post-TraumaticVeteransYoung AdultConceptsPost-traumatic stress disorderNegative Syndrome ScaleSyndrome ScalePTSD samplePlacebo-controlled trialPsychosis-related factorsClinical trial patientsClinical Antipsychotic TrialsT-testSchizophrenia sampleExploratory factor analysisSymptoms of schizophreniaMilitary-related post-traumatic stress disorderSymptom structureAdjunctive risperidoneTrial patientsTraumatic Stress DisorderAntipsychotic TrialsSecondary data analysisSevere symptomsIndependent factorsDepressive factorsPatientsSymptom ratingsStress disorderDifferences in Treatment Effect Among Clinical Subgroups in a Randomized Clinical Trial of Long-Acting Injectable Risperidone and Oral Antipsychotics in Unstable Chronic Schizophrenia
Leatherman SM, Liang MH, Krystal JH, Lew RA, Valley D, Thwin SS, Rosenheck RA. Differences in Treatment Effect Among Clinical Subgroups in a Randomized Clinical Trial of Long-Acting Injectable Risperidone and Oral Antipsychotics in Unstable Chronic Schizophrenia. The Journal Of Nervous And Mental Disease 2014, 202: 13-17. PMID: 24375206, DOI: 10.1097/nmd.0000000000000069.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAgedAntipsychotic AgentsChronic DiseaseDrug Administration ScheduleFemaleHospitalizationHumansInjections, IntramuscularMaleMiddle AgedProportional Hazards ModelsPsychotic DisordersQuality of LifeRisk AssessmentRisperidoneSchizophreniaSchizophrenic PsychologySeverity of Illness IndexSubstance-Related DisordersTreatment OutcomeConceptsQuality of lifeOral antipsychoticsOral treatmentInjectable risperidoneCox regressionTreatment effectsLong-Acting Injectable RisperidoneBody mass indexPsychiatric service useSubstance abuse outcomesSubstance use outcomesLAI risperidonePrimary endpointStudy entryWhite patientsClinical outcomesMass indexUnstable patientsMedication compliancePsychiatric rehospitalizationChronic schizophreniaClinical trialsClinical subgroupsPsychiatric hospitalizationPsychiatric symptoms
2013
Amygdala Connectivity Differs Among Chronic, Early Course, and Individuals at Risk for Developing Schizophrenia
Anticevic A, Tang Y, Cho YT, Repovs G, Cole MW, Savic A, Wang F, Krystal JH, Xu K. Amygdala Connectivity Differs Among Chronic, Early Course, and Individuals at Risk for Developing Schizophrenia. Schizophrenia Bulletin 2013, 40: 1105-1116. PMID: 24366718, PMCID: PMC4133672, DOI: 10.1093/schbul/sbt165.Peer-Reviewed Original ResearchConceptsHealthy comparison subjectsAmygdala connectivityHigh riskSymptom severityOrbitofrontal cortexWhole-brain functional connectivityHR individualsResting-state connectivitySchizophrenia symptom severityFunctional magnetic resonanceAmygdala seedArousal nucleiInitial episodeSchizophrenia neuropathologyChronic schizophreniaBrainstem regionsIllness phasePsychosis onsetElevated riskAmygdala circuitsEarly courseComparison subjectsFunctional alterationsClinical groupsFunctional connectivity
2011
Adjunctive Risperidone Treatment for Antidepressant-Resistant Symptoms of Chronic Military Service–Related PTSD: A Randomized Trial
Krystal JH, Rosenheck RA, Cramer JA, Vessicchio JC, Jones KM, Vertrees JE, Horney RA, Huang GD, Stock C, Group F. Adjunctive Risperidone Treatment for Antidepressant-Resistant Symptoms of Chronic Military Service–Related PTSD: A Randomized Trial. JAMA 2011, 306: 493-502. PMID: 21813427, DOI: 10.1001/jama.2011.1080.Peer-Reviewed Original ResearchConceptsMilitary-related posttraumatic stress disorderMontgomery-Asberg Depression Rating ScalePosttraumatic stress disorderClinical Global Impression ScaleClinician-Administered PTSD ScaleHamilton Anxiety ScalePlacebo-controlled multicenter trialCAPS scoresSelf-reported weight gainSecond-generation antipsychotic risperidoneAdjunctive risperidone treatmentAntidepressant-resistant symptomsPrimary outcome measureChronic military-related posttraumatic stress disorderGlobal Impression ScaleOutpatient medical centerDepression Rating ScaleSymptoms of depressionQuality of lifePlacebo groupRisperidone groupVeterans RANDAdverse eventsOngoing symptomsMulticenter trial
2003
Neurobiological Correlates of the Disposition and Maintenance of Alcoholism
Heinz A, Schäfer M, Higley J, Krystal J, Goldman D. Neurobiological Correlates of the Disposition and Maintenance of Alcoholism. Pharmacopsychiatry 2003, 36: 255-258. PMID: 14677088, DOI: 10.1055/s-2003-45139.Peer-Reviewed Original ResearchConceptsAlcohol effectsMaintenance of alcoholismCurrent disease conceptsNeurobiological foundationsDispositional factorsNeurobiological correlatesMotivational therapyConsequences of alcoholismAlcohol cravingReward systemAlcohol intakeClinical withdrawalReduced controlTreatment of alcoholismChronic alcohol effectsNew treatment optionsNeuroadaptationsResearch pointsRelapse riskMonoaminergic dysfunctionPatient groupTreatment optionsGlutamatergic neurotransmissionCentral GABAergicPharmacological approaches
2001
Lamotrigine in the treatment of depersonalization disorder.
Sierra M, Phillips M, Lambert M, Senior C, David A, Krystal J. Lamotrigine in the treatment of depersonalization disorder. The Journal Of Clinical Psychiatry 2001, 62: 826-7. PMID: 11816874, DOI: 10.4088/jcp.v62n1012b.Peer-Reviewed Original ResearchElevated motor threshold in drug-free, cocaine-dependent patients assessed with transcranial magnetic stimulation
Boutros N, Lisanby S, Tokuno H, Torello M, Campbell D, Berman R, Malison R, Krystal J, Kosten T. Elevated motor threshold in drug-free, cocaine-dependent patients assessed with transcranial magnetic stimulation. Biological Psychiatry 2001, 49: 369-373. PMID: 11239908, DOI: 10.1016/s0006-3223(00)00948-3.Peer-Reviewed Original ResearchConceptsTranscranial magnetic stimulationCortical excitabilityCocaine-dependent subjectsMotor thresholdControl subjectsMagnetic stimulationSingle-pulse transcranial magnetic stimulationExcitatory/inhibitory balancePulse transcranial magnetic stimulationChronic cocaine abuseMotor cortical regionsChronic cocaine abusersNormal control subjectsNumber of neurotransmittersAlters cortical excitabilityCocaine-dependent patientsCortical inhibitoryCerebral cortexInhibitory balanceAwake subjectsChronic cocaineCocaine intoxicationCocaine abusePsychiatric populationsCortical regions
1999
NMDA Agonists and Antagonists as Probes of Glutamatergic Dysfunction and Pharmacotherapies in Neuropsychiatric Disorders
Krystal J, D'Souza C, Petrakis I, Belger A, Berman R, Charney D, AbiSaab W, Madonick S. NMDA Agonists and Antagonists as Probes of Glutamatergic Dysfunction and Pharmacotherapies in Neuropsychiatric Disorders. Harvard Review Of Psychiatry 1999, 7: 125-143. PMID: 10483932, DOI: 10.3109/hrp.7.3.125.Peer-Reviewed Original ResearchConceptsN-methyl-D-aspartate (NMDA) subclassChronic pain syndromePain syndromeGlutamatergic dysfunctionNMDA agonistClinical studiesMajor depressionNMDA antagonistsGlutamate receptorsCoagonist siteParkinson's diseaseHuman psychopharmacological studiesPartial agonistAlzheimer's diseaseNeuropsychiatric conditionsNeuropsychiatric disordersDiseasePsychopharmacological studiesAnxiety disordersHuntington's diseaseAgonistsAntagonistTherapeutic hypothesesDisordersAddiction disordersReport of the Institute of Medicine Committee on the Efficacy and Safety of Halcion
Bunney W, Azarnoff D, Brown B, Cancro R, Gibbons R, Gillin J, Hullett S, Killam K, Kupfer D, Krystal J, Stolley P, French G, Pope A. Report of the Institute of Medicine Committee on the Efficacy and Safety of Halcion. JAMA Psychiatry 1999, 56: 349-352. PMID: 10197830, DOI: 10.1001/archpsyc.56.4.349.Peer-Reviewed Original ResearchAdverse Drug Reaction Reporting SystemsChronic DiseaseDrug ApprovalDrug EvaluationEvaluation Studies as TopicHumansHypnotics and SedativesNational Academies of Science, Engineering, and Medicine, U.S., Health and Medicine DivisionPrevalenceProduct Surveillance, PostmarketingProfessional Staff CommitteesRandomized Controlled Trials as TopicResearch DesignSleep Initiation and Maintenance DisordersTriazolamUnited StatesUnited States Food and Drug Administration
1992
Valproate Management of Psychosis in a Patient with Carbamazepine-Induced Hyponatremia
KARPER L, SEIBYL J, KRYSTAL J. Valproate Management of Psychosis in a Patient with Carbamazepine-Induced Hyponatremia. Journal Of Clinical Psychopharmacology 1992, 12: 137-138. PMID: 1573038, DOI: 10.1097/00004714-199204000-00015.Peer-Reviewed Original Research